HOME > TOP STORIES

TOP STORIES

BUSINESS Ono Joins SGLT-2 Inhibitor Battle via Copromotion Deal with AstraZeneca

December 4, 2013
BUSINESS Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later

December 3, 2013
BUSINESS Merck to Shed 200 Jobs in Japan by 2015

December 3, 2013
BUSINESS GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut

December 2, 2013
BUSINESS AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada

November 29, 2013
REGULATORY MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC

November 28, 2013
BUSINESS President Hasegawa of Takeda Confident About Achieving Targets in Midterm Growth Strategy; Company to Appoint CIO

November 28, 2013
BUSINESS Azilva Tops Physician “Mind Share” Ranking in GP, HP Markets in October: New Survey

November 27, 2013
BUSINESS Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma

November 27, 2013
ACADEMIA All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato

November 26, 2013
BUSINESS Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan

November 26, 2013
BUSINESS AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs

November 25, 2013
BUSINESS Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases

November 22, 2013
BUSINESS Japan Diovan Sales Down 15.7% in July-September: IMS

November 22, 2013
REGULATORY JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree

November 21, 2013
BUSINESS Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda

November 21, 2013
BUSINESS US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry

November 20, 2013
ACADEMIA JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials

November 19, 2013
REGULATORY PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29

November 19, 2013
BUSINESS Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery

November 18, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…